Leah Sherwood

Articles by Leah Sherwood

Leah SherwoodAggressive B-Cell Lymphoma | December 5, 2022
A combination of rituximab, lenalidomide, and ibrutinib produced a high overall response rate in newly diagnosed DLBCL.
Read More
Leah SherwoodAggressive B-Cell Lymphoma | December 5, 2022
Ibrutinib treatment was associated with higher survival rates in patients with mantle cell lymphoma (MCL) and CNS relapse.
Leah SherwoodMyeloproliferative Neoplasms | December 1, 2022
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Leah SherwoodTransplantation & Cellular Therapy | November 29, 2022
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
The National Comprehensive Cancer Network publishes new MPN guidelines.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
Researchers published new classifications for MPNs and acute leukemias.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
Those with MF with high molecular and cytogenetic risk do not benefit from higher intensity conditioning before transplant.
Leah SherwoodAggressive B-Cell Lymphoma | November 29, 2022
End of treatment high-dose methotrexate did not increase risk of CNS relapse compared with intercalated delivery.
Leah SherwoodChronic Myeloid Leukemia | November 23, 2022
Jorge Cortes, MD, discusses the financial toxicity of FDA-approved drugs for malignant hematology and OPTIC trial results.